Psoriasis Area and Severity Index 50 as an endpoint in psoriasis trials: An unconvincing proposal [17]

Journal of the American Academy of Dermatology

Volumn 53, Issue 3, 2005, Pages 546-550

  Katz, Kenneth A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; HUMAN; LETTER; MEASUREMENT; PATIENT; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 23944457124     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.06.017     Document Type: Letter

References (16)

1. C.S. Carlin, S.R. Feldman, J.G. Krueger, A. Menter, and G.G. Krueger A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis J Am Acad Dermatol 50 2004 859 866
2. D.M. Ashcroft, A.L. Wan Po, H.C. Williams, and C.E. Griffiths Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality Br J Dermatol 141 1999 185 191
3. Report of the Dermatologic and Ophthalmic Drugs Advisory Committee 49th meeting, open session. Rockville, Md: US Food and Drug Administration; March 1998. Available at: URL: http://www.fda.gov/ohrms/dockets/ac/98/transcpt/3402t2. rtf. Accessed November 12, 2004.
4. V.M. Heydendael, P.I. Spuls, B.C. Opmeer, C.A. de Borgie, J.B. Reitsma, and W.F. Goldschmidt Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis N Engl J Med 349 2003 658 665
5. K. Sandhu, I. Kaur, B. Kumar, and A. Saraswat Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from North India J Dermatol 30 2003 458 463
6. M. Lebwohl, E. Christophers, R. Langley, J.P. Ortonne, J. Roberts, and C.E. Griffiths An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis Arch Dermatol 139 2003 719 727
7. C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, and A. Wang Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022
8. U. Chaudhari, P. Romano, L.D. Mulcahy, L.T. Dooley, D.G. Baker, and A.B. Gottlieb Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial Lancet 357 2001 1842 1847
9. A.B. Gottlieb, R. Evans, S. Li, L.T. Dooley, C.A. Guzzo, and D. Baker Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 2004 534 542
10. G.G. Krueger, S.R. Feldman, C. Camisa, M. Duvic, J.T. Elder, and A.B. Gottlieb Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 43 2000 281 285
11. A.B. Gottlieb, R.T. Matheson, N. Lowe, G.G. Krueger, S. Kang, and B.S. Goffe A randomized trial of etanercept as monotherapy for psoriasis Arch Dermatol 139 2003 1627 1632
12. M. Lebwohl, S.K. Tyring, T.K. Hamilton, D. Toth, S. Glazer, and N.H. Tawfik A novel targeted T-cell modulator, efalizumab, for plaque psoriasis N Engl J Med 349 2003 2004 2013
13. K.B. Gordon, K.A. Papp, T.K. Hamilton, P.A. Walicke, W. Dummer, and N. Li Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial JAMA 290 2003 3073 3080
14. G.G. Krueger, K.A. Papp, D.B. Stough, K.H. Loven, W.P. Gulliver, and C.N. Ellis A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis J Am Acad Dermatol 47 2002 821 833
15. Hamilton DP. New battleground for biotech drugs: autoimmune ills. Wall Street Journal November 5, 2003;sect A:1.
16. R.S. Stern A promising step forward in psoriasis therapy JAMA 290 2003 3133 3135